ClinicalTrials.gg
RecruitingNCT05340348LONGIPEPUpdated Jun 26, 2026

Patientheque in Patients With a Psychosis

An interventional study of Blood samples (36 mL) + fecal samples + hair sample in Schizophrenia Prodromal, Schizophrenia, Childhood and Schizophrenia, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 15 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
15 Years to 30 Years
Sex
All
01

Study summary

Establishment of a patient library for patients who have had a first psychotic episode and who have an "at risk" status for psychotic disorder (GRD, APS, BLIPS group) or a psychosis threshold during CAARMS administration. Samples are taken on inclusion, at 2 years, and if relapse or significant clinical event within 5 years of inclusion, on 250 patients for 10 years.

Read the detailed description

The constitution of this patient library will include results of clinical tests carried out in current practice, neurocognitive tests, blood samples, audio recordings, clinical follow-up, urine samples, fecal samples, brain imaging, EEG.

02

Conditions studied

  • Schizophrenia Prodromal
  • Schizophrenia, Childhood
  • Schizophrenia

Keywords

  • Schizophrenia
  • Patient library
03

In context

Schizotypal Personality Disorder

49 studies on the registry are indexed under Schizotypal Personality Disorder; 12 are open to participants now.

This study's planned enrollment of 250 is above the median of 54 across 41 interventional studies indexed under Schizotypal Personality Disorder.

Browse Schizotypal Personality Disorder studies →

Lead sponsor

University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major and or minor aged 15 to 30 assessed within the CEVUP (Consultation for the Assessment of Psychological Vulnerability) and cared for at the psychiatry center as part of a first psychotic episode (Diagnosis CIM 10: F20 -F29 first hospitalization). These patients are referred by care and medico-social partners (general practitioners, school doctors, school nurses, educators, addictologists, psychiatrists
  • "At risk" status for psychotic disorder (GRD, APS, BLIPS group) or psychosis threshold during the CAARMS test (psychometric scale for the assessment of psychotic symptoms)
  • Consent of the patient or his legal guardian

Exclusion criteria

Exclusion Criteria:

  • History of psychosis for more than one year
  • "Not at risk" status for psychotic disorder on the CAARMS (psychometric scale for the assessment of psychotic symptomatology)
  • IQ\<70 (WAIS)
  • Neurological disorder or other health problem that may explain the disorders
  • Refusal to participate - History of psychosis for more than one year
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Other
    Patient library

    All the patients are included in one arm. They will undergo various type of samples.

    Other: Blood samples (36 mL) + fecal samples + hair sample

Interventions

  • OtherBlood samples (36 mL) + fecal samples + hair sample

    Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion

    Also known as: Patient library

06

What researchers measure

Primary outcomes

  1. CAARMS (Comprehensive assessment of at-risk mental states) score.

    The test will determine the mental state of the patient : * "Not at risk of psychosis" * "At risk of psychosis" * "Psychosis threshold exceeded" It is organized into 7 clinical dimensions: 1) positive symptoms 2) cognitive changes: attention / concentration 3) emotional disturbance 4) negative symptoms 5) behavioral change 6) physical and motor changes 7) general psychopathology. Each category is scored between 0 and 6 depending on the level of intensity, frequency and duration of each symptom. In order to determine if a subject meets the UHR criteria for CAARMS, only the first category (positive symptoms) and its four subscales are used according to a scoring algorithm.

    Time frame: 5 years

Secondary outcomes

  1. CAARMS sub-assemblies

    If the patient is classified at risk of psychosis, the test will classify this risk into one of the three following categories : trait and state risk factor group, APS (attenuated psychotic symptoms) group, BLIPS (Brief, Limited or Intermittent Psychotic Symptoms) group.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

Time frame: Data will be available after the publication of result and ending fifteen years following the last visit of the last patient

Access criteria: Data access requests will be reviewed by the internal committee of Brest University Hospital (UH). Requestors will be required to sign and complete a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2032, 120 months after the start.

Of 20 interventional studies with no phase under Schizotypal Personality Disorder, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2022
First posted
Apr 22, 2022
StartActual
Jul 25, 2022
Primary completionEst.
Jul 25, 2032
CompletionEst.
Jul 25, 2032
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05340348
Responsible party
Sponsor
First posted
Apr 22, 2022
Start date
Jul 25, 2022
Primary completion
Jul 25, 2032 (estimated)
Completion
Jul 25, 2032 (estimated)
Last update
Jun 26, 2026

Study contacts

Michel WALTER
Contact
michel.walter@chu-brest.fr
+332 98 01 51 56
Christophe LEMEY
Contact
christophe.lemey@chu-brest.fr
+336 19 21 10 32
Michel WALTER
principal investigator · CHRU BREST

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion